Clinical Trial Update: Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the combination of Orelabrutinib with a Hi-CVP regimen for previously untreated marginal zone lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Marginal Zone Lymphoma

Drugs mentioned

• Orelabrutinib (orelabrutinib)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Marginal Zone Lymphoma(MZL) | Phase 2 | Status: ACTIVE_NOT_RECRUITING